Rubedo Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 34

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Latest Deal Amount
  • $68.1K

  • Investors
  • 27

Rubedo General Information

Description

Operator of a biopharmaceutical company intended to commercialize novel therapeutics that target and eliminate senescent cells. The company's platform utilizes selective apoptosis of cells in aged or pathological tissues to create tissue regeneration, enabling patients to extend their health span, improve the functions of good cells, and treat age-related diseases.

Contact Information

Website
www.rubedolife.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 428 Oakmead Parkingway
  • Sunnyvale, CA 94085
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 428 Oakmead Parkingway
  • Sunnyvale, CA 94085
  • United States

Rubedo Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rubedo Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Accelerator/Incubator 04-Jun-2026 $68.1K Completed Clinical Trials - Phase 1
5. Later Stage VC (Series B) 23-Oct-2025 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series A) 25-Jul-2024 Completed Clinical Trials - Phase 1
3. Grant 06-Feb-2023 Completed Clinical Trials - Phase 1
2. Seed Round 15-Nov-2021 $12M $12M Completed Clinical Trials - Phase 1
1. Accelerator/Incubator 01-Jun-2018 Completed Clinical Trials - Phase 1
To view Rubedo’s complete valuation and funding history, request access »

Rubedo Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A-2
Series A
Seed 3A
Seed 3
Seed 2 1,715,686 $0.000100 8% $1.02 $1.02 1x $1.02 4.81%
Seed 1 441,251 $0.000100 8% $0.74 $0.74 1x $0.74 1.24%
To view Rubedo’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Rubedo Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to commercialize novel therapeutics that target and eliminate senescent
Drug Discovery
Sunnyvale, CA
34 As of 2026

San Carlos, CA
 

Emeryville, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Rubedo Competitors (3)

One of Rubedo’s 3 competitors is Alkahest, a Formerly VC-backed company based in San Carlos, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alkahest Formerly VC-backed San Carlos, CA
BioAge Labs Formerly VC-backed Emeryville, CA
Longeveron Formerly VC-backed Miami, FL
You’re viewing 3 of 3 competitors. Get the full list »

Rubedo Patents

  • 51

    Total Documents Applications and Grants

  • Total Patents Families

  • 9

    Granted

  • 24

    Pending

  • Expiring in next 12 mo

Rubedo Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250296951-A1 Gpx4 inhibitors and senolytic compounds and uses thereof Pending 19-Mar-2024
WO-2025199126-A1 Gpx4 inhibitors and senolytic compounds and uses thereof Pending 19-Mar-2024
AU-2024389419-A1 Carbon linked bcl inhibitors and senolytic compounds and uses thereof Pending 27-Nov-2023
EP-4791387-A1 Carbon linked bcl inhibitors and senolytic compounds and uses thereof Pending 27-Nov-2023
US-20250171435-A1 Carbon linked bcl inhibitors and senolytic compounds and uses thereof Pending 27-Nov-2023 A61K31/5377
To view Rubedo’s complete patent history, request access »

Rubedo Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rubedo Investors (27)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hub71 Accelerator/Incubator
Alumni Ventures Venture Capital Minority
Beiersdorf Corporation Minority
Beiersdorf Venture Capital Corporate Venture Capital Minority
B-Engine Venture Capital Minority
You’re viewing 5 of 27 investors. Get the full list »

Ready to get started?

Request a free trial

Rubedo FAQs

  • When was Rubedo founded?

    Rubedo was founded in 2018.

  • Where is Rubedo headquartered?

    Rubedo is headquartered in Sunnyvale, CA.

  • What is the size of Rubedo?

    Rubedo has 34 total employees.

  • What industry is Rubedo in?

    Rubedo’s primary industry is Drug Discovery.

  • Is Rubedo a private or public company?

    Rubedo is a Private company.

  • What is Rubedo’s current revenue?

    The current revenue for Rubedo is .

  • How much funding has Rubedo raised over time?

    Rubedo has raised $52.1M.

  • Who are Rubedo’s investors?

    Hub71, Alumni Ventures, Beiersdorf, Beiersdorf Venture Capital, and B-Engine are 5 of 27 investors who have invested in Rubedo.

  • Who are Rubedo’s competitors?

    Alkahest, BioAge Labs, and Longeveron are competitors of Rubedo.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process